SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Adline Chem Lab Ltd (524604)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524604 NSE: Pharmaceuticals & Drugs | Small Cap | Adline Chem Lab Share Price

₹13.70 0.00 (0.00%)

As on 22-May'26 16:59

Adline Chem Lab Ltd (524604)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524604 NSE: Pharmaceuticals & Drugs | Small Cap | Adline Chem Lab Share Price

₹13.70 0.00 (0.00%)

As on 22-May'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹8 Cr.
Current Price
₹13.7
52-Week Low / High
₹8 / 19
TTM EPS
₹-0.1
TTM Sales
₹0 Cr.
Book Value per Share
₹-2.8
P/E Ratio
0.00
Industry PE
46.5
Price to Book (P/B)
-4.98
Lower than its 5-year historical median
Price to Sales (P/S)
0.00
EV/EBITDA
-2359.78
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
0.00%
Underperforms industry median
Return on Capital Employed (ROCE)
0.00%
Underperforms industry median
Return on Assets (ROA)
-224.83%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
25.85%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-7 Cr.
Equity
₹5.9 Cr.
Face Value
₹10
All Time Low / High
₹4.75 / 28.97

Adline Chem Lab stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Adline Chem Lab Ltd a good quality company?
Adline Chem Lab Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Adline Chem Lab Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Adline Chem Lab Ltd vs industry peers?
Adline Chem Lab Ltd revenue CAGR is -100.00%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Adline Chem Lab Ltd?
Promoters hold 25.85% of the Adline Chem Lab Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Adline Chem Lab Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 21.85% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Adline Chem Lab Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 3.2%2.5%2.6%0.9%-49.4%-23.8%16.2%-227%0%0%-
Value Creation
Index
-0.8-0.8-0.8-0.9-4.5-2.70.2NANANA-

Growth Parameters

Sales 16.716.98.15.66.66.30.70000
Sales YoY Gr.-1.1%-52%-31%17.9%-4%-88.3%-100%NANA-
Adj EPS 0000-6.7-2.21.2-2-0.5-0.2-0.1
YoY Gr.--66.7%-100%NA-16925%NANA-265.9%NANA-
BVPS (₹) 8.26.14.64.65.53.34.5-2.7-2.4-2.6-2.8
Adj Net
Profit
0000-3.9-1.30.7-1.2-0.3-0.1-0
Cash Flow from Ops. 0.82.51.1-1-11.3-0.30.20-0.2-0.2-
Debt/CF from Ops. 10.8410.8-5.7-0.3-8.56.296.1-8-6.6-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -100%-100%-100%NA
Adj EPS -225.4%NA-157.2%NA
BVPS-187.8%-185.8%-182.6%NA
Share Price - 21.9% 30% -11.6%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
0.20.100.3-76.8-49.931.4-220.718.59.23.8
Op. Profit
Mgn %
2.67.28.79.8-50.5-3.7-40.2000NAN
Net Profit
Mgn %
0.10.100.4-59.7-20.397.4000-INF
Debt to
Equity
1.92.84.220.91.30.5-0.9-1-1-
Working Cap
Days
1311102173382261416300000
Cash Conv.
Cycle
63561442421561044450000

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales16.6716.868.105.596.596.330.74000
Operating Expenses + 16.2315.647.405.059.926.561.030.800.180.29
Manufacturing Costs0.340.340.240.170.410.130.05000
Material Costs13.0512.764.611.424.883.030.480.2600
Employee Cost 1.381.151.201.331.781.560.170.050.040.18
Other Costs 1.461.391.352.122.861.840.330.490.130.12
Operating Profit 0.431.220.700.55-3.33-0.24-0.30-0.80-0.18-0.29
Operating Profit Margin (%) 2.6%7.2%8.7%9.8%-50.5%-3.7%-40.2%---
Other Income + 0.110.080.380.290.020.010.18100.25
Exceptional Items 00000.2401.14-4.3500
Interest 0.440.320.340.070.020.030.0100.120.16
Depreciation 0.090.960.730.730.421.020.350.0900
Profit Before Tax 0.020.010.010.03-3.51-1.280.67-4.23-0.30-0.21
Tax 0.0100.0100.260-0.050-0.03-0.07
Profit After Tax 0.010.0100.03-3.76-1.280.72-4.23-0.27-0.13
PAT Margin (%) 0.1%0.1%0.0%0.5%-57.1%-20.3%97.4%---
Adjusted EPS (₹)0.00.00.00.1-6.4-2.21.2-7.2-0.5-0.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Adline Chem Lab - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 7.067.047.037.033.211.932.65-1.57-1.37-1.49
Share Capital 5.855.855.855.855.855.855.855.855.855.85
Reserves 1.211.191.181.18-2.64-3.92-3.20-7.42-7.22-7.34
Debt +9.019.9411.325.352.852.501.321.331.361.49
Long Term Debt4.294.153.770000001.49
Short Term Debt4.725.797.555.352.852.501.321.331.360
Minority Interest0000000000
Trade Payables1.481.720.801.700.560.240.45000
Others Liabilities 0.872.254.217.770.960.970.460.300.060.08
Total Liabilities 18.4220.9623.3621.857.585.634.870.060.040.08

Fixed Assets

Net Fixed Assets +10.2712.6812.4511.994.783.644.43000
Gross Block15.2718.6519.1819.466.295.635.57000
Accumulated Depreciation55.986.737.481.511.991.14000
CWIP 0.20000000000
Investments 0000000000
Inventories1.651.942.293.241.090.390.26000
Trade Receivables2.502.652.282.081.431.580.07000
Cash Equivalents flag 0.220.131.680.170.05-0.160.050.060.040.06
Others Assets 3.583.564.654.370.230.170.06000.01
Total Assets 18.4220.9623.3621.857.585.634.870.060.040.08

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 0.832.461.05-0.95-11.34-0.290.210.01-0.17-0.23
PBT 0.010.010.010.03-3.76-1.280.72-4.23-0.30-0.21
Adjustment 0.441.280.900.800.201.06-0.834.450.12-0.10
Changes in Working Capital 0.391.170.14-1.78-7.77-0.070.32-0.20.01-0.02
Tax Paid 0000000000.10
Cash Flow From Investing Activity + -0.21-3.18-3.03-0.2811.240.120000
Capex -0.21-3.19-0.53-0.2911.240.120000
Net Investments 0000000000
Others 00-2.500.01000000
Cash Flow From Financing Activity + -0.780.633.54-0.29-0.02-0.03-0.0100.150.25
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -0.44-0.32-0.34-0.07-0.02-0.03-0.010-0.12-0.13
Dividend Paid 0000000000
Others -0.340.953.88-0.2200000.270.38
Net Cash Flow -0.15-0.091.56-1.51-0.12-0.210.200.01-0.020.02

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)0.20.210.061.02-127.09-49.8931.35N/AN/AN/A
ROCE (%)3.162.462.550.93-49.36-23.8216.18N/AN/AN/A
Asset Turnover Ratio0.910.870.370.250.450.960.14000
PAT to CFO Conversion(x)83246N/A-31.67N/AN/A0.29N/AN/AN/A
Working Capital Days
Receivable Days53.1054.70110.20142.2097.3086.90409.80000
Inventory Days43.2038.1094.50180.40119.9042.80161.30000
Payable Days3945.90100320.2084.3047.70259.90000

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Adline Chem Lab Ltd FAQs

The current trading price of Adline Chem Lab on 22-May-2026 16:59 is ₹13.70.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-May-2026 the market cap of Adline Chem Lab stood at ₹8.01 Cr

The latest P/E ratio of Adline Chem Lab as of 21-May-2026 is 0.00.

The latest P/B ratio of Adline Chem Lab as of 21-May-2026 is -4.98.

The 52-week high of Adline Chem Lab is ₹19.08 and the 52-week low is ₹7.60.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Adline Chem Lab is ₹0.00 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Adline Chem Lab Ltd is a below average quality company.

The key valuation ratios of Adline Chem Lab Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Adline Chem Lab Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Adline Chem Lab Ltd

No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×